temozolomide has been researched along with Pituitary Neoplasms in 131 studies
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies." | 8.95 | Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. ( Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS, 2017) |
| "There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas." | 8.90 | Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. ( Hirohata, T; Hoya, K; Ide, F; Ishii, Y; Matsuno, A; Miyamoto, S; Mizutani, A; Murakami, M; Nagashima, H; Nishido, H; Okinaga, H; Osamura, RY; Son, JH; Sugaya, M; Tahara, S; Teramoto, A; Yamada, S; Yamada, SM, 2014) |
| "Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas." | 8.88 | Temozolomide in aggressive pituitary adenomas and carcinomas. ( Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, 2012) |
| "Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging." | 7.96 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. ( Bojunga, J; Buchfelder, M; Buslei, R; Deutschbein, T; Droste, M; Elbelt, U; Honegger, J; Johanssen, S; Knappe, UJ; Kolenda, H; Lammert, A; Micko, A; Petersenn, S; Ritzel, K; Schlaffer, SM; Strasburger, CJ; Topuzoglu-Müller, T; Unger, N; Vila, G, 2020) |
| "To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA)." | 7.91 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. ( Aharon-Hananel, G; Badarna, M; Percik, R; Tirosh, A; Uri, I, 2019) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 7.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "Temozolomide is effective in some patients with progressive pituitary adenoma or carcinoma." | 7.83 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. ( Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C, 2016) |
| "Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide." | 7.83 | HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy. ( Bin, X; Bingbing, X; Dongchun, W; Kun, Z; Xiaoli, L; Yuling, Y, 2016) |
| " Descriptions of aggressive pituitary tumors and pituitary carcinomas have increased notably over the last decade following the first report on the successful treatment of pituitary carcinomas using temozolomide." | 7.83 | Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. ( Lasolle, H; Raverot, G, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) activity is responsible for temozolomide (TMZ) resistance in patients harboring aggressive pituitary adenomas." | 7.81 | Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. ( Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y, 2015) |
| "Invasive pituitary adenomas (PAs) are often refractory to standard therapy and salvage treatment with temozolomide (TMZ)." | 7.79 | Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. ( Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H, 2013) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 7.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "To date only 18 patients with aggressive pituitary tumors or carcinomas treated with temozolomide have been reported." | 7.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "This was a 1-year prospective study of temozolomide therapy in six consecutive patients with pituitary carcinoma (one case) or atypical pituitary adenoma (five cases) resistant to standard therapies." | 7.76 | Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. ( Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR, 2010) |
| "Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors." | 7.01 | Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. ( Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C, 2023) |
| "Temozolomide (TMZ) was proposed as a treatment option for pituitary carcinomas and aggressive pituitary adenomas." | 6.74 | O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? ( Czech, T; Knosp, E; Kotter, MR; Marosi, C; Preusser, M; Widhalm, G; Woehrer, A; Wolfsberger, S, 2009) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 6.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression." | 6.47 | Treatment of pituitary neoplasms with temozolomide: a review. ( Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H, 2011) |
| "Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal multimodality therapy." | 5.62 | Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. ( Ahuja, CK; Bhansali, A; Das, L; Dhandapani, S; Dutta, P; Gupta, K; Gupta, N; Radotra, BD; Rai, A; Sood, R; Sreedharanunni, S; Tripathi, M; Vaiphei, K; Walia, R, 2021) |
| "The optimal treatment of pituitary carcinomas (PC) is unknown." | 5.46 | Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. ( Hoostal, S; Lou, E; Peterson, RA; SantaCruz, KS; Touma, W; Wiernik, A, 2017) |
| "Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0." | 5.43 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. ( Arnal, AV; Donovan, LE; Odia, Y; Wang, SH, 2016) |
| "Aggressive pituitary adenomas (PAs) are clinically challenging for endocrinologists and neurosurgeons due to their locally invasive nature and resistance to standard treatment (surgery, medical or radiotherapy)." | 5.42 | Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. ( Bertorelle, R; Boscaro, M; Ceccato, F; D'Avella, D; Denaro, L; Emanuelli, E; Gardiman, MP; Lombardi, G; Manara, R; Milanese, L; Occhi, G; Scanarini, M; Scaroni, C; Zagonel, V, 2015) |
| "Temozolomide (TMZ) is an oral alkylating drug with good tolerability, approved for treatment of malignant gliomas." | 5.42 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ, 2015) |
| "The established first-line medical therapy for refractory adenomas is temozolomide, which importantly may increase survival, but clinical trial data are still needed to clearly establish its efficacy, identify biomarkers of response, and clarify eligibility and outcome criteria." | 5.41 | Medical therapy for refractory pituitary adenomas. ( Geer, EB, 2023) |
| "Pituitary carcinoma is extremely rare and difficult to diagnose early." | 5.40 | Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management. ( Jiang, S; Yin, S; Zhong, C; Zhou, P, 2014) |
| "Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas." | 5.39 | DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. ( Amano, K; Arita, K; Asano, K; Fujio, S; Fukuhara, N; Hirohata, T; Hizuka, N; Ikeda, H; Ishii, Y; Isozaki, O; Iwai, Y; Kawamata, T; Matsuno, A; Nishioka, H; Ogawa, Y; Osamura, RY; Sakata, K; Shimatsu, A; Tahara, S; Takano, K; Takano, S; Teramoto, A; Tominaga, A; Yamada, S, 2013) |
| "Pituitary carcinomas are rare and neurosurgically challenging lesions, as they commonly relapse after surgical removal." | 5.36 | SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. ( Back, W; Bode, H; Brockmann, MA; Hammes, HP; Lammert, A; Seiz, M; Thomé, C, 2010) |
| "Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors." | 5.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "Once temozolomide has failed, there is no recommended treatment option for pituitary carcinomas and aggressive pituitary tumors." | 5.22 | Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. ( Ilie, MD; Jouanneau, E; Raverot, G; Vasiljevic, A, 2022) |
| "Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients." | 5.05 | Prolactinomas in males: any differences? ( Duskin-Bitan, H; Shimon, I, 2020) |
| " Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies." | 4.95 | Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. ( Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS, 2017) |
| " More recently, temozolomide, a second generation oral alkylating agent, has shown therapeutic promise for aggressive pituitary adenomas and carcinomas with favorable clinical and radiographic responses." | 4.91 | The role of temozolomide in the treatment of aggressive pituitary tumors. ( Eloy, JA; Liu, JK; Patel, J, 2015) |
| "There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas." | 4.90 | Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. ( Hirohata, T; Hoya, K; Ide, F; Ishii, Y; Matsuno, A; Miyamoto, S; Mizutani, A; Murakami, M; Nagashima, H; Nishido, H; Okinaga, H; Osamura, RY; Son, JH; Sugaya, M; Tahara, S; Teramoto, A; Yamada, S; Yamada, SM, 2014) |
| " Recent evidence suggests that temozolomide (TMZ), an orally-active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas." | 4.88 | Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. ( Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL, 2012) |
| "Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas." | 4.88 | Temozolomide in aggressive pituitary adenomas and carcinomas. ( Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, 2012) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that has recently been used in some cases as a new therapeutic tool for pituitary carcinomas and aggressive pituitary adenomas." | 4.86 | Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ( Altavilla, G; Cannavò, S; Curtò, L; Ferraù, F; Granata, F; Hofland, LJ; Longo, M; Pitini, V; Torre, ML; Trimarchi, F, 2010) |
| "After temozolomide failure, no evidence-based treatment is available for pituitary carcinomas (PCs) and aggressive pituitary tumors (APTs)." | 4.12 | Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. ( Assie, G; Baussart, B; Cancel, M; Chanson, P; Cortet, C; Cuny, T; Decoudier, B; Deluche, E; Di Stefano, AL; Drui, D; Gaillard, S; Goichot, B; Huillard, O; Ilie, MD; Joncour, A; Larrieu-Ciron, D; Libe, R; Nars, G; Raverot, G; Vasiljevic, A; Villa, C, 2022) |
| "Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging." | 3.96 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. ( Bojunga, J; Buchfelder, M; Buslei, R; Deutschbein, T; Droste, M; Elbelt, U; Honegger, J; Johanssen, S; Knappe, UJ; Kolenda, H; Lammert, A; Micko, A; Petersenn, S; Ritzel, K; Schlaffer, SM; Strasburger, CJ; Topuzoglu-Müller, T; Unger, N; Vila, G, 2020) |
| " Temozolomide (TMZ) has been proposed in patients with aggressive pituitary neuroendocrine tumors (PitNETs) who do not respond to conventional treatments." | 3.91 | Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. ( Albiger, N; Ceccato, F; Lombardi, G; Mazzai, L; Pambuku, A; Rolma, G; Scaroni, C; Zagonel, V, 2019) |
| "To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA)." | 3.91 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. ( Aharon-Hananel, G; Badarna, M; Percik, R; Tirosh, A; Uri, I, 2019) |
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 3.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "Temozolomide is effective in some patients with progressive pituitary adenoma or carcinoma." | 3.83 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. ( Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C, 2016) |
| "Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide." | 3.83 | HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy. ( Bin, X; Bingbing, X; Dongchun, W; Kun, Z; Xiaoli, L; Yuling, Y, 2016) |
| " Descriptions of aggressive pituitary tumors and pituitary carcinomas have increased notably over the last decade following the first report on the successful treatment of pituitary carcinomas using temozolomide." | 3.83 | Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. ( Lasolle, H; Raverot, G, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) activity is responsible for temozolomide (TMZ) resistance in patients harboring aggressive pituitary adenomas." | 3.81 | Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. ( Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y, 2015) |
| "To study the expression of D2R, MGMT and VEGF for clinical significance in pituitary adenomas, and to predict the potential curative medical therapy of dopamine agonists, temozolomide and bevacizumab on pituitary adenomas." | 3.80 | The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. ( Hu, Y; Li, J; Li, W; Lu, Z; Ma, C; Tohti, M; Wang, S; Wang, Y, 2014) |
| "Invasive pituitary adenomas (PAs) are often refractory to standard therapy and salvage treatment with temozolomide (TMZ)." | 3.79 | Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. ( Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H, 2013) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "MGMT promoter hypermethylation of aggressive pituitary adenomas and pituitary carcinomas and low protein expression are implicated in improved response to treatment with temozolomide (TMZ)." | 3.77 | MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. ( Erickson, D; Fealey, M; Horvath, E; Kovacs, K; Kros, JM; Lau, Q; Lloyd, RV; Salehi, F; Scheithauer, BW, 2011) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 3.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Recent publications suggest the utility of temozolomide (TMZ) in the management of aggressive pituitary adenomas and carcinomas, resistant to conventional treatments." | 3.77 | MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. ( Altuntaş, Y; Çil, E; Karaman, Ö; Müslüman, AM; Özkayalar, H; Öztürk, FY; Tanik, C; Velet, S; Zuhur, SS, 2011) |
| "The objective of the study was to assess O(6)-methylguanine-DNA methyltransferase (MGMT) immunoreactivity in pituitary adenomas of silent subtype 3 as a potential indicator of temozolomide susceptibility." | 3.76 | MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. ( Erickson, D; Fealey, ME; Horvath, E; Kovacs, K; Lloyd, RV; McLendon, R; Scheithauer, BW, 2010) |
| "To date only 18 patients with aggressive pituitary tumors or carcinomas treated with temozolomide have been reported." | 3.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "This was a 1-year prospective study of temozolomide therapy in six consecutive patients with pituitary carcinoma (one case) or atypical pituitary adenoma (five cases) resistant to standard therapies." | 3.76 | Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. ( Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR, 2010) |
| "Three cases of patients with pituitary adenomas who underwent temozolomide treatment are presented." | 3.75 | Use of temozolomide in aggressive pituitary tumors: case report. ( Cusimano, MD; Kovacs, K; Mason, W; Mohammed, S; Smyth, H, 2009) |
| "Non-functioning pituitary adenomas (NFPAs) comprise silent tumors of different pituitary lineages that tend to escape early detection and present as invasive macroadenomas with symptoms of mass effect." | 3.01 | Refractory nonfunctioning pituitary adenomas. ( Greenman, Y; Kolitz, T, 2023) |
| "Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors." | 3.01 | Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. ( Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C, 2023) |
| "A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also demonstrate aggressive or even malignant behavior." | 3.01 | Refractory lactotroph adenomas. ( Karavitaki, N; Urwyler, SA, 2023) |
| "Everolimus is an active agent in the treatment of prolactinomas that warrants further investigation." | 3.01 | The treatment of aggressive prolactinomas with everolimus. ( Geer, EB; Lala, N; Lin, AL; Magge, R; Page-Wilson, G; Tabar, V; Young, RJ, 2023) |
| "Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors (APTs) and carcinomas present important diagnostic and therapeutic challenges and are associated with a high mortality rate." | 2.82 | Aggressive corticotroph tumors and carcinomas. ( Ilie, MD; Jouanneau, E; Lasolle, H; Raverot, G; Vasiljevic, A, 2022) |
| "Although pituitary adenomas (PAs) account for 15% of intracranial tumors, pituitary carcinomas (PCs) are a rare entity." | 2.82 | Pituitary carcinoma - case series and review of the literature. ( Andreescu, CE; Bruneau, M; Du Four, S; Duerinck, J; Neyns, B; Van Der Veken, J; Velkeniers, B; Velthoven, V; Vermeulen, E, 2022) |
| "Temozolomide (TMZ) was proposed as a treatment option for pituitary carcinomas and aggressive pituitary adenomas." | 2.74 | O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? ( Czech, T; Knosp, E; Kotter, MR; Marosi, C; Preusser, M; Widhalm, G; Woehrer, A; Wolfsberger, S, 2009) |
| "The rare aggressive pituitary adenoma presents a special challenge, due to the heterogenous presentation of the disease." | 2.72 | Medical Therapy of Aggressive Pituitary Tumors. ( Petersenn, S, 2021) |
| "Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life." | 2.72 | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. ( Araki, T; Kawakami, Y; Lau, KJ; McMahon, C; Nakano-Tateno, T; Tateno, T; Wang, J, 2021) |
| "Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia." | 2.72 | Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. ( Fukuoka, H; Nakao, T; Ogawa, W; Yamamoto, M, 2021) |
| "Aggressive prolactinomas are defined as radiologically invasive tumors which cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite dopamine agonist treatment and surgery." | 2.66 | Aggressive prolactinomas: how to manage? ( Ilie, MD; Lasolle, H; Raverot, G, 2020) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 2.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "With a prevalence of 80-100/100000, pituitary adenomas are more frequent than thought." | 2.61 | Management of Aggressive Pituitary Tumors - A 2019 Update. ( Petersenn, S, 2019) |
| "Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since 2006." | 2.61 | How and when to use temozolomide to treat aggressive pituitary tumours. ( Whitelaw, BC, 2019) |
| "Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome." | 2.58 | Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( Lenders, N; McCormack, A, 2018) |
| "Non-functioning pituitary adenomas (NFPAs) are in general large tumors that present with symptoms secondary to local pressure on adjacent structures." | 2.58 | Management of NFAs: medical treatment. ( Even-Zohar, N; Greenman, Y, 2018) |
| "Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma." | 2.58 | 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. ( Kovacs, K; Ortiz, LD; Rotondo, F; Syro, LV, 2018) |
| "Temozolomide (TMZ) has been reported to be useful as an adjunctive treatment for some patients." | 2.58 | Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. ( Barkhoudarian, G; Eisenberg, A; Kelly, DF; Ogunbameru, R; Palejwala, SK; Wei, H, 2018) |
| "Temozolomide (TMZ) has been shown as an effective treatment option in aggressive pituitary adenomas and carcinomas." | 2.55 | How effective is temozolomide for treating pituitary tumours and when should it be used? ( Halevy, C; Whitelaw, BC, 2017) |
| "Temozolomide is an oral chemotherapy with a favorable side-effect profile that has shown activity against pituitary adenomas." | 2.53 | Is there a role for early chemotherapy in the management of pituitary adenomas? ( DeAngelis, LM; Lin, AL; Sum, MW, 2016) |
| "Aggressive pituitary adenomas, defined from a clinical perspective, have earlier and more frequent recurrences and can be resistant to conventional treatments." | 2.50 | Aggressive pituitary adenomas--diagnosis and emerging treatments. ( Cusimano, MD; Di Ieva, A; Kovacs, K; Rotondo, F; Syro, LV, 2014) |
| "Atypical pituitary adenomas (APAs) are aggressive tumors, harboring a Ki-67 (MIB-1) staining index of 3% or more, and positive immunohistochemical staining for p53 protein, according to the World Health Organization (WHO) classification in 2004." | 2.50 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. ( Hirohata, T; Ishii, Y; Matsuno, A, 2014) |
| "Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma." | 2.49 | Temozolomide and unusual indications: review of literature. ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013) |
| "They may present initially as typical pituitary adenomas, with a delayed appearance of aggressive signs, or as aggressive tumours from the outset." | 2.48 | Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. ( Brue, T; Castinetti, F; Dufour, H; Figarella-Branger, D; Jouanneau, E; Morange, I; Raverot, G; Trouillas, J, 2012) |
| "A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression." | 2.47 | Treatment of pituitary neoplasms with temozolomide: a review. ( Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H, 2011) |
| "Dopamine agonist-resistant prolactinomas exhibit aggressive behavior and tend to be large, invasive, hyperangiogenic tumors with high mitotic indices, which makes their management via surgery, radiosurgery, or alternative medical therapies challenging, thus underscoring the need for novel medical therapies or treatment regimens that target these lesions." | 2.47 | Dopamine agonist-resistant prolactinomas. ( Aghi, MK; Oh, MC, 2011) |
| "The group included 30 pituitary carcinomas (15 ACTH, 10 PRL, 1 FSH/LH, 1 TSH, 1 silent subtype 3 and 2 null cell)." | 2.46 | MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. ( Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Scheithauer, B; Syro, LV, 2010) |
| "Aggressive pituitary adenomas are notoriously difficult to manage due to their size, invasiveness, speed of growth and high frequency of recurrence." | 2.45 | Management of aggressive pituitary adenomas: current treatment strategies. ( Buchfelder, M, 2009) |
| "Temozolomide has recently been used for atypical adenomas or pituitary carcinomas." | 2.45 | [Recent trends in the pathophysiology and treatment of pituitary adenomas]. ( Matsuno, A, 2009) |
| "Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with regard to clinical presentation, proliferative markers, clinical course, and response to therapy." | 1.91 | Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. ( Burman, P; Casar-Borota, O; Dekkers, OM; Perez-Rivas, LG, 2023) |
| "The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not metastasize, and were therefore called adenomas." | 1.91 | Aggressive pituitary tumors (PitNETs). ( Nishioka, H, 2023) |
| "Pituitary carcinomas are thus clinically defined by the presence of craniospinal or distant metastases, typically developing several years after the first presentation." | 1.91 | [Aggressive pituitary adenoma and pituitary carcinoma]. ( Tóth, M, 2023) |
| "Pre-temozolomide treatment, these data were 5." | 1.91 | Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. ( Araujo-Castro, M; Biagetti, B; Cámara, R; Fajardo, C; García-Centeno, R; Guerrero-Pérez, F; Hanzu, F; Iglesias, P; Lamas, C; Mora, M; Remon-Ruiz, P; Soto, A, 2023) |
| "Aggressive pituitary adenoma (APA) is a huge challenge for neurosurgeons." | 1.72 | MicroRNA-146b-5p/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4/TRAF6/NF-κB signaling pathway in aggressive pituitary adenoma. ( Cai, Y; Lou, X; Zhang, Y; Zheng, H, 2022) |
| "Temozolomide (TMZ) is a recommended treatment option, but its effects are difficult to predict, and the alternatives are limited." | 1.72 | Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay. ( Fukuoka, H; Inoshita, N; Ishida, A; Ogawa, W; Shichi, H; Yamada, S, 2022) |
| "Temozolomide therapy was initiated after surveillance MRI showed recurrence at 16 months postoperatively." | 1.72 | Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report. ( Bhabhra, R; Forbes, JA; Golnik, K; Hagen, M; Lin, AL; Mahammedi, A; Manzoor, S; Pater, L; Rothman, Y; Sengupta, S; Shah, S, 2022) |
| "We concluded that dopamine resistant prolactinomas undergo a β-Catenin relocalization in relation to normal pituitaries and that TMZ restrains experimental prolactinoma tumorigenicity by reducing PRL production and β-Catenin activation." | 1.72 | β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models. ( Alaniz, L; Berner, S; Bonadeo, N; Cervio, A; Chimento, A; Cristina, C; Demarchi, G; Perrone, S; Sevlever, G; Spinelli, FM; Valla, S; Vitale, DL, 2022) |
| "Temozolomide treatment in 156/171 patients resulted in complete response in 9." | 1.72 | Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. ( Burman, P; Dekkers, OM; Losa, M; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Theodoropoulou, M; Trouillas, J, 2022) |
| "Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal multimodality therapy." | 1.62 | Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. ( Ahuja, CK; Bhansali, A; Das, L; Dhandapani, S; Dutta, P; Gupta, K; Gupta, N; Radotra, BD; Rai, A; Sood, R; Sreedharanunni, S; Tripathi, M; Vaiphei, K; Walia, R, 2021) |
| "Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists (DAs) are troublesome, and surgery often only removes a large part of the tumor without complete remission." | 1.62 | Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. ( Cheng, Y; Huang, J; Li, J; Tang, H; Wu, ZB; Zhang, B, 2021) |
| "Aggressive pituitary adenomas and pituitary carcinomas are rare and demand multiple treatment strategies." | 1.46 | Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. ( Chen, C; Hu, Y; Jiang, S; Wang, M; Yin, S; Zhang, S; Zhou, P, 2017) |
| "Although pituitary adenomas are considered benign lesions, a small group may show clinically aggressive behavior, sometimes independently from the classic markers of aggressiveness, including the Ki67 labeling index or p53 expression." | 1.46 | Aggressive Pituitary Adenomas: The Dark Side of the Moon. ( Abbritti, RV; Angileri, FF; Baldari, S; Barresi, V; Cannavò, S; Conti, A; Esposito, F; Ferraù, F; Germanò, A; Priola, SM; Tomasello, F, 2017) |
| "The optimal treatment of pituitary carcinomas (PC) is unknown." | 1.46 | Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. ( Hoostal, S; Lou, E; Peterson, RA; SantaCruz, KS; Touma, W; Wiernik, A, 2017) |
| "Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0." | 1.43 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. ( Arnal, AV; Donovan, LE; Odia, Y; Wang, SH, 2016) |
| "Prolactinomas are a rare subset of brain tumors in pediatrics." | 1.43 | Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. ( Felker, J; Janss, A; Patterson, B; Wrubel, D, 2016) |
| "Only pituitary tumors with cerebrospinal and/or systemic metastasis are considered malignant carcinomas." | 1.43 | Refractory pituitary adenoma: a novel classification for pituitary tumors. ( Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D, 2016) |
| "Aggressive pituitary adenomas (PAs) are clinically challenging for endocrinologists and neurosurgeons due to their locally invasive nature and resistance to standard treatment (surgery, medical or radiotherapy)." | 1.42 | Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. ( Bertorelle, R; Boscaro, M; Ceccato, F; D'Avella, D; Denaro, L; Emanuelli, E; Gardiman, MP; Lombardi, G; Manara, R; Milanese, L; Occhi, G; Scanarini, M; Scaroni, C; Zagonel, V, 2015) |
| "Temozolomide (TMZ) is an oral alkylating drug with good tolerability, approved for treatment of malignant gliomas." | 1.42 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ, 2015) |
| "Pituitary carcinoma is extremely rare and difficult to diagnose early." | 1.40 | Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management. ( Jiang, S; Yin, S; Zhong, C; Zhou, P, 2014) |
| "Temozolomide (TMZ) has been proposed as a therapeutic option in aggressive pituitary tumors." | 1.39 | Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. ( Batisse, M; Chazal, J; Durando, X; Kemeny, JL; Maqdasy, S; Montoriol, PF; Raverot, G; Sturm, N; Tauveron, I; Trouillas, J, 2013) |
| "Invasive pituitary adenomas (PAs) are generally refractory to conventional therapy and salvage treatment with temozolomide (TMZ)." | 1.39 | Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. ( Bao, X; Cai, F; Dai, C; Deng, K; Feng, M; Guo, K; Jiao, Y; Junji, W; Lian, W; Liu, X; Ma, S; Wang, R; Wei, Z; Xing, B; Yang, Y; Yao, Y; Zhang, B, 2013) |
| "Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas." | 1.39 | DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. ( Amano, K; Arita, K; Asano, K; Fujio, S; Fukuhara, N; Hirohata, T; Hizuka, N; Ikeda, H; Ishii, Y; Isozaki, O; Iwai, Y; Kawamata, T; Matsuno, A; Nishioka, H; Ogawa, Y; Osamura, RY; Sakata, K; Shimatsu, A; Tahara, S; Takano, K; Takano, S; Teramoto, A; Tominaga, A; Yamada, S, 2013) |
| "Everolimus treatment was inefficient at controlling secretion and tumor growth of one ACTH pituitary carcinoma." | 1.38 | New targeted therapies in pituitary carcinoma resistant to temozolomide. ( Borson-Chazot, F; Ducray, F; Favrel, V; Honnorat, J; Jouanneau, E; Raverot, G; Trouillas, J; Wierinckx, A, 2012) |
| "Temozolomide is an oral alkylating agent approved for glioblastoma multiforme treatment that has only recently shown promise in treating some pituitary tumors." | 1.37 | Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. ( Delashaw, JB; Dillard, TH; Fleseriu, M; Gultekin, SH; Neuwelt, EA; Yedinak, CG, 2011) |
| "Temozolomide is an alkylating chemotherapeutic agent used routinely in the management of high grade gliomas." | 1.37 | MGMT immunoexpression in adamantinomatous craniopharyngiomas. ( Altuntaş, Y; Aydın, Y; Karaman, O; Müslüman, AM; Ozderya, A; Ozkayalar, H; Oztürk, FY; Tanık, C; Zuhur, SS, 2011) |
| "Pituitary carcinomas are rare and neurosurgically challenging lesions, as they commonly relapse after surgical removal." | 1.36 | SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. ( Back, W; Bode, H; Brockmann, MA; Hammes, HP; Lammert, A; Seiz, M; Thomé, C, 2010) |
| "The typically indolent behavior of pituitary tumors is juxtaposed with high rates of tumor cell invasion into adjacent dural structures, and occasional aggressive behavior." | 1.36 | Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. ( Bush, ZM; Cunningham, T; Jane, JA; Laws, ER; Longtine, JA; Lopes, MB; Schiff, D; Thorner, MO; Vance, ML, 2010) |
| "We report a case of pituitary carcinoma with multiple craniospinal metastases in a child." | 1.35 | Pituitary carcinoma presenting with multiple metastases: case report. ( Cayli, SR; Guzel, A; Guzel, E; Sav, A; Senturk, S; Tatli, M, 2008) |
| "Temozolomide (TMZ) is an alkylating cytostaticum." | 1.35 | Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. ( Andersen, M; Hagen, C; Hansen, S; Schroeder, HD, 2009) |
| "He had initially been diagnosed with prolactinoma some years before and had undergone multiple craniotomies to debulk recurrent metastatic lesions." | 1.35 | A novel use of temozolomide in a patient with malignant prolactinoma. ( Byrne, S; Karapetis, C; Vrodos, N, 2009) |
| "Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors." | 1.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "Prolactinomas are common tumors of the anterior pituitary gland." | 1.34 | Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. ( Cole, A; Hedges, TR; Lawrence, D; Lechan, RM; Neff, LM; Shucart, W; Tischler, AS; Weil, M; Zhu, JJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (11.45) | 29.6817 |
| 2010's | 77 (58.78) | 24.3611 |
| 2020's | 39 (29.77) | 2.80 |
| Authors | Studies |
|---|---|
| Raverot, G | 17 |
| Ilie, MD | 7 |
| Lasolle, H | 5 |
| Amodru, V | 1 |
| Trouillas, J | 9 |
| Castinetti, F | 4 |
| Brue, T | 4 |
| Wildemberg, LE | 1 |
| Fialho, C | 1 |
| Gadelha, MR | 1 |
| Lou, X | 1 |
| Cai, Y | 1 |
| Zheng, H | 1 |
| Zhang, Y | 1 |
| Ishida, A | 1 |
| Shichi, H | 1 |
| Fukuoka, H | 2 |
| Inoshita, N | 3 |
| Ogawa, W | 2 |
| Yamada, S | 5 |
| Mirallas, O | 1 |
| Filippi-Arriaga, F | 1 |
| Hernandez Hernandez, I | 1 |
| Aubanell, A | 1 |
| Chaachou, A | 1 |
| Garcia-Alvarez, A | 1 |
| Hernando, J | 1 |
| Martínez-Saez, E | 1 |
| Biagetti, B | 2 |
| Capdevila, J | 1 |
| Stelmachowska-Banaś, M | 1 |
| Maksymowicz, M | 1 |
| Kolasińska-Ćwikła, A | 1 |
| Zieliński, G | 1 |
| Korbonits, M | 2 |
| Zgliczyński, W | 1 |
| Das, L | 1 |
| Gupta, N | 1 |
| Dutta, P | 2 |
| Walia, R | 1 |
| Vaiphei, K | 1 |
| Rai, A | 2 |
| Radotra, BD | 2 |
| Gupta, K | 1 |
| Sreedharanunni, S | 1 |
| Ahuja, CK | 1 |
| Bhansali, A | 2 |
| Tripathi, M | 1 |
| Sood, R | 1 |
| Dhandapani, S | 1 |
| Borhan, MK | 1 |
| Tan, FHS | 1 |
| Vasiljevic, A | 4 |
| Jouanneau, E | 7 |
| Shah, S | 1 |
| Manzoor, S | 1 |
| Rothman, Y | 1 |
| Hagen, M | 1 |
| Pater, L | 1 |
| Golnik, K | 1 |
| Mahammedi, A | 1 |
| Lin, AL | 3 |
| Bhabhra, R | 1 |
| Forbes, JA | 1 |
| Sengupta, S | 1 |
| Demarchi, G | 2 |
| Valla, S | 1 |
| Perrone, S | 2 |
| Chimento, A | 1 |
| Bonadeo, N | 1 |
| Vitale, DL | 1 |
| Spinelli, FM | 1 |
| Cervio, A | 1 |
| Sevlever, G | 2 |
| Alaniz, L | 1 |
| Berner, S | 1 |
| Cristina, C | 2 |
| Esper Romero, G | 1 |
| De Bonis, C | 1 |
| Casasco, JP | 1 |
| Berner, SI | 1 |
| Burman, P | 7 |
| Losa, M | 5 |
| McCormack, A | 8 |
| Petersenn, S | 6 |
| Popovic, V | 3 |
| Theodoropoulou, M | 2 |
| Dekkers, OM | 4 |
| Villa, C | 2 |
| Cuny, T | 1 |
| Cortet, C | 2 |
| Assie, G | 2 |
| Baussart, B | 1 |
| Cancel, M | 1 |
| Chanson, P | 3 |
| Decoudier, B | 1 |
| Deluche, E | 1 |
| Di Stefano, AL | 1 |
| Drui, D | 1 |
| Gaillard, S | 3 |
| Goichot, B | 2 |
| Huillard, O | 1 |
| Joncour, A | 1 |
| Larrieu-Ciron, D | 1 |
| Libe, R | 1 |
| Nars, G | 1 |
| Du Four, S | 1 |
| Van Der Veken, J | 1 |
| Duerinck, J | 1 |
| Vermeulen, E | 1 |
| Andreescu, CE | 1 |
| Bruneau, M | 1 |
| Neyns, B | 1 |
| Velthoven, V | 1 |
| Velkeniers, B | 1 |
| Kolitz, T | 1 |
| Greenman, Y | 2 |
| Casar-Borota, O | 1 |
| Perez-Rivas, LG | 1 |
| Nishioka, H | 3 |
| Padovan, M | 1 |
| Cerretti, G | 1 |
| Caccese, M | 1 |
| Barbot, M | 2 |
| Bergo, E | 1 |
| Occhi, G | 2 |
| Scaroni, C | 5 |
| Lombardi, G | 5 |
| Ceccato, F | 5 |
| Urwyler, SA | 1 |
| Karavitaki, N | 1 |
| Geer, EB | 2 |
| Lala, N | 1 |
| Page-Wilson, G | 1 |
| Magge, R | 1 |
| Young, RJ | 1 |
| Tabar, V | 1 |
| Tóth, M | 1 |
| Lamas, C | 1 |
| Cámara, R | 1 |
| Fajardo, C | 1 |
| Remon-Ruiz, P | 1 |
| Guerrero-Pérez, F | 1 |
| Araujo-Castro, M | 1 |
| Mora, M | 1 |
| Hanzu, F | 1 |
| Iglesias, P | 1 |
| García-Centeno, R | 1 |
| Soto, A | 1 |
| Kontogeorgos, G | 2 |
| Thodou, E | 2 |
| Koutourousiou, M | 1 |
| Kaltsas, G | 1 |
| Seretis, A | 1 |
| Elbelt, U | 1 |
| Schlaffer, SM | 1 |
| Buchfelder, M | 2 |
| Knappe, UJ | 1 |
| Vila, G | 2 |
| Micko, A | 1 |
| Deutschbein, T | 1 |
| Unger, N | 1 |
| Lammert, A | 2 |
| Topuzoglu-Müller, T | 1 |
| Bojunga, J | 1 |
| Droste, M | 1 |
| Johanssen, S | 1 |
| Kolenda, H | 1 |
| Ritzel, K | 1 |
| Buslei, R | 1 |
| Strasburger, CJ | 1 |
| Honegger, J | 1 |
| Duskin-Bitan, H | 1 |
| Shimon, I | 1 |
| Lamb, L | 1 |
| Lizzul, L | 1 |
| Gardiman, MP | 2 |
| Regazzo, D | 1 |
| Bellu, L | 1 |
| Mazza, E | 3 |
| Nakano-Tateno, T | 2 |
| Satou, M | 1 |
| van Landeghem, FKH | 1 |
| Easaw, J | 1 |
| Mehta, V | 1 |
| Tateno, T | 2 |
| Chik, CL | 1 |
| Tang, H | 1 |
| Cheng, Y | 1 |
| Huang, J | 1 |
| Li, J | 2 |
| Zhang, B | 3 |
| Wu, ZB | 1 |
| Lau, KJ | 1 |
| Wang, J | 2 |
| McMahon, C | 1 |
| Kawakami, Y | 1 |
| Araki, T | 1 |
| Yamamoto, M | 1 |
| Nakao, T | 1 |
| Cloix, L | 1 |
| Caron, P | 2 |
| Delemer, B | 1 |
| Desailloud, R | 1 |
| Jublanc, C | 1 |
| Lebrun-Frenay, C | 1 |
| Sadoul, JL | 1 |
| Taillandier, L | 1 |
| Batisse-Lignier, M | 1 |
| Bonnet, F | 1 |
| Bourcigaux, N | 1 |
| Bresson, D | 1 |
| Chabre, O | 2 |
| Garcia, C | 2 |
| Haissaguerre, M | 1 |
| Reznik, Y | 1 |
| Borot, S | 1 |
| Almalki, MH | 1 |
| Aljoaib, NN | 1 |
| Alotaibi, MJ | 1 |
| Aldabas, BS | 1 |
| Wahedi, TS | 1 |
| Ahmad, MM | 1 |
| Alshahrani, F | 1 |
| Micko, ASG | 1 |
| Wöhrer, A | 1 |
| Höftberger, R | 1 |
| Marosi, C | 2 |
| Knosp, E | 2 |
| Wolfsberger, S | 2 |
| Bilbao, I | 1 |
| Egaña, N | 1 |
| Olaizola, I | 1 |
| van der Vlist, A | 1 |
| Snijders, TJ | 1 |
| Stades, AME | 1 |
| Spliet, WGM | 1 |
| De Vos, FYFL | 1 |
| Lenders, N | 1 |
| Even-Zohar, N | 1 |
| Chen, C | 1 |
| Yin, S | 2 |
| Zhang, S | 1 |
| Wang, M | 1 |
| Hu, Y | 2 |
| Zhou, P | 2 |
| Jiang, S | 2 |
| Syro, LV | 10 |
| Rotondo, F | 5 |
| Ortiz, LD | 8 |
| Kovacs, K | 14 |
| Barkhoudarian, G | 1 |
| Palejwala, SK | 1 |
| Ogunbameru, R | 1 |
| Wei, H | 1 |
| Eisenberg, A | 1 |
| Kelly, DF | 1 |
| Bengtsson, D | 2 |
| Schrøder, HD | 2 |
| Berinder, K | 2 |
| Maiter, D | 2 |
| Hoybye, C | 2 |
| Ragnarsson, O | 2 |
| Feldt-Rasmussen, U | 1 |
| Krogh Rasmussen, Å | 1 |
| van der Lely, A | 1 |
| Petersson, M | 2 |
| Johannsson, G | 2 |
| Andersen, M | 3 |
| Albiger, N | 1 |
| Mazzai, L | 1 |
| Pambuku, A | 1 |
| Rolma, G | 1 |
| Zagonel, V | 2 |
| Reddy, KS | 1 |
| Madugundu, AK | 1 |
| Solanki, HS | 1 |
| Kumar, N | 1 |
| Collier, D | 1 |
| Iacovazzo, D | 2 |
| Gupta, P | 1 |
| Raja, R | 1 |
| Gowda, H | 1 |
| Pandey, A | 1 |
| Devgun, JS | 1 |
| Aharon-Hananel, G | 1 |
| Percik, R | 1 |
| Badarna, M | 1 |
| Uri, I | 1 |
| Tirosh, A | 1 |
| Whitelaw, BC | 2 |
| Batisse, M | 1 |
| Maqdasy, S | 1 |
| Durando, X | 2 |
| Sturm, N | 2 |
| Montoriol, PF | 1 |
| Kemeny, JL | 1 |
| Chazal, J | 1 |
| Tauveron, I | 1 |
| Dai, C | 3 |
| Liu, X | 3 |
| Guo, K | 2 |
| Ma, S | 3 |
| Cai, F | 2 |
| Yang, Y | 2 |
| Yao, Y | 3 |
| Feng, M | 3 |
| Bao, X | 3 |
| Deng, K | 2 |
| Jiao, Y | 1 |
| Wei, Z | 1 |
| Junji, W | 1 |
| Xing, B | 3 |
| Lian, W | 3 |
| Wang, R | 3 |
| Sareen, P | 1 |
| Chhabra, L | 1 |
| Trivedi, N | 1 |
| Matsuno, A | 5 |
| Murakami, M | 2 |
| Hoya, K | 1 |
| Yamada, SM | 1 |
| Miyamoto, S | 1 |
| Son, JH | 1 |
| Nishido, H | 1 |
| Ide, F | 1 |
| Nagashima, H | 1 |
| Sugaya, M | 1 |
| Hirohata, T | 3 |
| Mizutani, A | 2 |
| Okinaga, H | 2 |
| Ishii, Y | 3 |
| Tahara, S | 2 |
| Teramoto, A | 2 |
| Osamura, RY | 2 |
| Chen, W | 2 |
| Xiao, Z | 2 |
| Zhao, Y | 2 |
| Huang, L | 1 |
| Du, G | 1 |
| Zairi, F | 1 |
| Aboukais, R | 1 |
| Maurage, CA | 1 |
| Assaker, R | 2 |
| Di Ieva, A | 1 |
| Cusimano, MD | 2 |
| Wang, Y | 2 |
| Tohti, M | 1 |
| Wang, S | 1 |
| Li, W | 1 |
| Lu, Z | 1 |
| Ma, C | 1 |
| Zhong, C | 1 |
| Manara, R | 1 |
| Emanuelli, E | 1 |
| Denaro, L | 1 |
| Milanese, L | 1 |
| Bertorelle, R | 1 |
| Scanarini, M | 1 |
| D'Avella, D | 1 |
| Boscaro, M | 1 |
| Strowd, RE | 1 |
| Salvatori, R | 1 |
| Laterra, JJ | 1 |
| Feldt Rasmussen, U | 1 |
| Rasmussen, ÅK | 1 |
| van der Lely, AJ | 1 |
| Liu, JK | 1 |
| Patel, J | 1 |
| Eloy, JA | 1 |
| Yang, J | 1 |
| Li, T | 1 |
| Fan, B | 1 |
| Bogazzi, F | 1 |
| Cannavo, S | 3 |
| Curtò, L | 2 |
| De Marinis, L | 1 |
| Mantovani, G | 1 |
| Minniti, G | 1 |
| Nizzoli, M | 1 |
| Reni, M | 2 |
| Kun, Z | 1 |
| Yuling, Y | 1 |
| Dongchun, W | 1 |
| Bingbing, X | 1 |
| Xiaoli, L | 1 |
| Bin, X | 1 |
| Kamiya-Matsuoka, C | 1 |
| Cachia, D | 1 |
| Waguespack, SG | 1 |
| Crane, CH | 1 |
| Mahajan, A | 1 |
| Brown, PD | 1 |
| Nam, JY | 1 |
| McCutcheon, IE | 1 |
| Penas-Prado, M | 1 |
| Sum, MW | 1 |
| DeAngelis, LM | 1 |
| Halevy, C | 1 |
| Donovan, LE | 1 |
| Arnal, AV | 1 |
| Wang, SH | 1 |
| Odia, Y | 1 |
| Priola, SM | 1 |
| Esposito, F | 1 |
| Conti, A | 1 |
| Abbritti, RV | 1 |
| Barresi, V | 1 |
| Baldari, S | 1 |
| Ferraù, F | 2 |
| Germanò, A | 1 |
| Tomasello, F | 1 |
| Angileri, FF | 1 |
| Felker, J | 1 |
| Patterson, B | 1 |
| Wrubel, D | 1 |
| Janss, A | 1 |
| Sun, B | 1 |
| Zhong, D | 1 |
| Ma, W | 2 |
| Todeschi, J | 1 |
| Chibbaro, S | 1 |
| Clavier, JB | 1 |
| Lhermitte, B | 1 |
| Proust, F | 1 |
| Touma, W | 1 |
| Hoostal, S | 1 |
| Peterson, RA | 1 |
| Wiernik, A | 1 |
| SantaCruz, KS | 1 |
| Lou, E | 1 |
| McCormack, AI | 2 |
| McDonald, KL | 1 |
| Gill, AJ | 3 |
| Clark, SJ | 1 |
| Burt, MG | 1 |
| Campbell, KA | 1 |
| Braund, WJ | 1 |
| Little, NS | 1 |
| Cook, RJ | 1 |
| Grossman, AB | 2 |
| Robinson, BG | 1 |
| Clifton-Bligh, RJ | 1 |
| Guzel, A | 1 |
| Tatli, M | 1 |
| Senturk, S | 1 |
| Guzel, E | 1 |
| Cayli, SR | 1 |
| Sav, A | 1 |
| Widhalm, G | 1 |
| Preusser, M | 1 |
| Woehrer, A | 1 |
| Kotter, MR | 1 |
| Czech, T | 1 |
| Mohammed, S | 1 |
| Mason, W | 1 |
| Smyth, H | 1 |
| Takeshita, A | 1 |
| Taguchi, M | 1 |
| Okuda, C | 1 |
| Fukuhara, N | 3 |
| Oyama, K | 1 |
| Ohashi, K | 1 |
| Sano, T | 1 |
| Takeuchi, Y | 1 |
| Hagen, C | 2 |
| Schroeder, HD | 1 |
| Hansen, S | 1 |
| Byrne, S | 1 |
| Karapetis, C | 1 |
| Vrodos, N | 1 |
| Alameda Hernando, C | 1 |
| Lahera Vargas, M | 1 |
| Varela Da Costa, C | 1 |
| Fealey, ME | 1 |
| Scheithauer, BW | 7 |
| Horvath, E | 9 |
| Erickson, D | 2 |
| McLendon, R | 1 |
| Lloyd, RV | 2 |
| Bode, H | 1 |
| Seiz, M | 1 |
| Brockmann, MA | 1 |
| Back, W | 1 |
| Hammes, HP | 1 |
| Thomé, C | 1 |
| Dobson, M | 1 |
| Del Porto, L | 1 |
| Maartens, NF | 1 |
| de Fraipont, F | 1 |
| Muller, M | 1 |
| Salenave, S | 1 |
| Cortet-Rudelli, C | 1 |
| Dufour, H | 3 |
| François, P | 1 |
| Passagia, JG | 1 |
| Bernier, M | 1 |
| Cornélius, A | 1 |
| Figarella-Branger, D | 2 |
| Borson-Chazot, F | 2 |
| Bush, ZM | 1 |
| Longtine, JA | 1 |
| Cunningham, T | 1 |
| Schiff, D | 1 |
| Jane, JA | 1 |
| Vance, ML | 1 |
| Thorner, MO | 1 |
| Laws, ER | 1 |
| Lopes, MB | 1 |
| Lau, Q | 3 |
| Scheithauer, B | 1 |
| Lloyd, R | 2 |
| Gonzalez, R | 1 |
| Uribe, H | 7 |
| Cusimano, M | 1 |
| Terreni, MR | 1 |
| Motta, M | 1 |
| Cangi, MG | 1 |
| Talarico, A | 1 |
| Mortini, P | 1 |
| Dillard, TH | 1 |
| Gultekin, SH | 1 |
| Delashaw, JB | 1 |
| Yedinak, CG | 1 |
| Neuwelt, EA | 1 |
| Fleseriu, M | 1 |
| Torre, ML | 1 |
| Pitini, V | 1 |
| Altavilla, G | 1 |
| Granata, F | 1 |
| Longo, M | 1 |
| Hofland, LJ | 1 |
| Trimarchi, F | 1 |
| Oh, MC | 1 |
| Aghi, MK | 1 |
| Salehi, F | 1 |
| Kros, JM | 1 |
| Fealey, M | 1 |
| Zuhur, SS | 2 |
| Müslüman, AM | 2 |
| Tanık, C | 2 |
| Karaman, O | 2 |
| Oztürk, FY | 2 |
| Ozderya, A | 1 |
| Ozkayalar, H | 2 |
| Aydın, Y | 1 |
| Altuntaş, Y | 2 |
| Asano, S | 1 |
| Katakami, H | 1 |
| Ozawa, Y | 1 |
| Yamazaki, K | 1 |
| Ishida, Y | 1 |
| Takano, K | 2 |
| Wass, JA | 1 |
| Hueng, DY | 1 |
| Ma, HI | 1 |
| Sytwu, HK | 1 |
| Liu, MY | 1 |
| Velet, S | 1 |
| Çil, E | 1 |
| Wierinckx, A | 1 |
| Ducray, F | 1 |
| Favrel, V | 1 |
| Honnorat, J | 1 |
| Ersen, A | 2 |
| Fadul, CE | 4 |
| Annamalai, AK | 1 |
| Dean, AF | 1 |
| Kandasamy, N | 1 |
| Burton, H | 1 |
| Halsall, DJ | 1 |
| Shaw, AS | 1 |
| Antoun, NM | 1 |
| Cheow, HK | 1 |
| Kirollos, RW | 1 |
| Pickard, JD | 1 |
| Simpson, HL | 1 |
| Jefferies, SJ | 1 |
| Burnet, NG | 1 |
| Gurnell, M | 1 |
| Morange, I | 2 |
| Philippon, M | 1 |
| Barrie, M | 1 |
| Barlier, A | 1 |
| Taieb, D | 1 |
| Conte-Devolx, B | 1 |
| Kaplan, W | 1 |
| Little, N | 1 |
| Cook, R | 1 |
| Robinson, B | 1 |
| Clifton-Bligh, R | 1 |
| Tatar, Z | 1 |
| Thivat, E | 1 |
| Planchat, E | 1 |
| Gimbergues, P | 1 |
| Gadea, E | 1 |
| Abrial, C | 1 |
| Penagos, L | 1 |
| Asano, K | 1 |
| Ogawa, Y | 1 |
| Takano, S | 1 |
| Amano, K | 1 |
| Isozaki, O | 1 |
| Iwai, Y | 1 |
| Sakata, K | 1 |
| Fujio, S | 1 |
| Arita, K | 1 |
| Tominaga, A | 1 |
| Hizuka, N | 1 |
| Ikeda, H | 1 |
| Kawamata, T | 1 |
| Shimatsu, A | 1 |
| Li, G | 1 |
| Xiao, J | 1 |
| Zhang, H | 1 |
| Lim, S | 1 |
| Shahinian, H | 1 |
| Maya, MM | 1 |
| Yong, W | 1 |
| Heaney, AP | 1 |
| Penagos, LC | 3 |
| Rook, J | 1 |
| Rosser, T | 1 |
| Fangusaro, J | 1 |
| Finlay, J | 1 |
| Neff, LM | 1 |
| Weil, M | 1 |
| Cole, A | 1 |
| Hedges, TR | 1 |
| Shucart, W | 1 |
| Lawrence, D | 1 |
| Zhu, JJ | 1 |
| Tischler, AS | 1 |
| Lechan, RM | 1 |
| Lombardero, M | 1 |
| McLendon, RE | 1 |
46 reviews available for temozolomide and Pituitary Neoplasms
| Article | Year |
|---|---|
Aggressive pituitary tumours and pituitary carcinomas.
Topics: Craniopharyngioma; Humans; Immunotherapy; Pituitary Neoplasms; Temozolomide; Tumor Microenvironment | 2021 |
Prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon | 2021 |
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Topics: Carcinoma; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Pituitary Neoplasms; Temozolomide | 2022 |
Aggressive corticotroph tumors and carcinomas.
Topics: Adenoma; Carcinoma; Corticotrophs; Humans; Pituitary Neoplasms; Temozolomide | 2022 |
Pituitary carcinoma - case series and review of the literature.
Topics: Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Humans; Pituitary Neoplasms | 2022 |
Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Systematic Reviews as T | 2022 |
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.
Topics: Biomarkers, Tumor; Humans; Immunotherapy; Microsatellite Instability; Mutation; Pituitary Neoplasms; | 2022 |
Refractory nonfunctioning pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Tem | 2023 |
Refractory lactotroph adenomas.
Topics: Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Somatostatin; Temozolomide | 2023 |
Medical therapy for refractory pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
The treatment of aggressive prolactinomas with everolimus.
Topics: Dopamine Agonists; Everolimus; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2023 |
Aggressive prolactinomas: how to manage?
Topics: Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2020 |
Prolactinomas in males: any differences?
Topics: Cabergoline; Dopamine Agonists; Humans; Hypogonadism; Male; Pituitary Neoplasms; Prolactinoma; Somat | 2020 |
Management of Aggressive Pituitary Tumors - A 2019 Update.
Topics: Animals; Antineoplastic Agents; Humans; Pituitary Neoplasms; Temozolomide | 2019 |
Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Humans; Neoplasm Invasiveness; Pituitary Neoplasms; Temozolomide | 2020 |
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma | 2020 |
Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
Topics: Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Gonadotrophs; Human | 2020 |
Medical Therapy of Aggressive Pituitary Tumors.
Topics: Antineoplastic Agents; Bevacizumab; Enzyme Inhibitors; Humans; Immune Checkpoint Inhibitors; Pituita | 2021 |
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Topics: Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Dopamine Agonists; Humans; Pituitary | 2021 |
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Carcinoma; Dopamine Agonists | 2021 |
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Prolactinoma | 2017 |
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Topics: Adenoma; Animals; Cell Transformation, Neoplastic; Dacarbazine; Humans; Pituitary Neoplasms; Temozol | 2018 |
Management of NFAs: medical treatment.
Topics: Adenoma; Dacarbazine; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Temozolomide | 2018 |
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
Topics: Animals; Antineoplastic Agents, Alkylating; Humans; Pituitary Neoplasms; Temozolomide | 2018 |
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Neoplasm Recurrence, Loca | 2018 |
How and when to use temozolomide to treat aggressive pituitary tumours.
Topics: Antineoplastic Agents, Alkylating; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosi | 2019 |
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA-Binding Proteins; Hu | 2014 |
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkyl | 2014 |
Aggressive pituitary adenomas--diagnosis and emerging treatments.
Topics: Adenoma; Biomarkers, Tumor; Dacarbazine; Humans; Ki-67 Antigen; Neoplasm Invasiveness; Neovasculariz | 2014 |
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; C | 2014 |
The role of temozolomide in the treatment of aggressive pituitary tumors.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DN | 2015 |
Is there a role for early chemotherapy in the management of pituitary adenomas?
Topics: Adenoma; Antineoplastic Agents; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2016 |
How effective is temozolomide for treating pituitary tumours and when should it be used?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pi | 2017 |
Management of aggressive pituitary adenomas: current treatment strategies.
Topics: Cabergoline; Dacarbazine; Dopamine Agonists; Ergolines; Female; Humans; Male; Pituitary Neoplasms; S | 2009 |
[Recent trends in the pathophysiology and treatment of pituitary adenomas].
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines | 2009 |
[Treatment of clinically nonfunctioning pituitary adenomas].
Topics: Adenoma; Adult; Cranial Irradiation; Dacarbazine; Decompression, Surgical; Dopamine Agonists; Female | 2010 |
MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair | 2010 |
Treatment of pituitary neoplasms with temozolomide: a review.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modificat | 2011 |
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; | 2010 |
Dopamine agonist-resistant prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Cell Division; Dacarbazine; Dopamine Agonists; Drug Resistance, N | 2011 |
[Pituitary carcinoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged; Pituitary Neoplasms; Te | 2011 |
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dru | 2012 |
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Hum | 2012 |
Temozolomide in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Tem | 2012 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
1 trial available for temozolomide and Pituitary Neoplasms
| Article | Year |
|---|---|
O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Mod | 2009 |
84 other studies available for temozolomide and Pituitary Neoplasms
| Article | Year |
|---|---|
MicroRNA-146b-5p/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4/TRAF6/NF-κB signaling pathway in aggressive pituitary adenoma.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplas | 2022 |
Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
Topics: Capecitabine; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2022 |
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Male; Middle Aged; Ne | 2021 |
Pituitary carcinoma as a rare cause of liver metastases successfully treated with temozolomide.
Topics: Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide | 2022 |
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Topics: Adenoma; Adult; Cohort Studies; Early Medical Intervention; Female; Humans; India; Male; Middle Aged | 2021 |
Aggressive giant prolactinoma: a case report.
Topics: Adolescent; Adult; Cabergoline; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Pro | 2022 |
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
Topics: Adenoma; DNA Mismatch Repair; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Pituitary Neo | 2022 |
β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Topics: Animals; beta Catenin; Cyclin D1; Humans; Mice; Models, Theoretical; Pituitary Neoplasms; Prolactin; | 2022 |
Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
Topics: Adenoma; Adrenocorticotropic Hormone; beta Catenin; Corticotrophs; Humans; Pituitary Neoplasms; Temo | 2022 |
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Topics: Adenoma; Adrenocorticotropic Hormone; Bevacizumab; Carcinoma; Female; Humans; Immune Checkpoint Inhi | 2022 |
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Topics: B7-H1 Antigen; Carcinoma; Cohort Studies; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Pitui | 2022 |
Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
Topics: Bevacizumab; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Aggressive pituitary tumors (PitNETs).
Topics: Adenoma; Carcinoma; Humans; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2023 |
Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question.
Topics: Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
[Aggressive pituitary adenoma and pituitary carcinoma].
Topics: Adenoma; Bevacizumab; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide | 2023 |
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Topics: Female; Humans; Male; Neuroendocrine Tumors; Pituitary Diseases; Pituitary Neoplasms; Retrospective | 2023 |
MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.
Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; | 2019 |
Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; DNA Modification Methylases; DNA Repair Enzyme | 2019 |
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Female; Germany; Humans; Male; Middle | 2020 |
Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Corticotrop | 2021 |
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.
Topics: Adult; Antineoplastic Agents, Alkylating; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Pr | 2021 |
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiothe | 2017 |
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzym | 2017 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Meningeal Neoplasms; Pituitary N | 2017 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Pituitary Neoplasms; Prola | 2017 |
Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Fem | 2018 |
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Cabergoline; Combined Modality Therapy; Cytoreduction Surgical Pr | 2019 |
Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.
Topics: Adenoma; Antineoplastic Protocols; Bevacizumab; Child, Preschool; Combined Modality Therapy; Human G | 2019 |
Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.
Topics: Adenoma; Aged; Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Israel; Male; Middle Ag | 2019 |
Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dru | 2013 |
Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspas | 2013 |
Primary undifferentiated spindle-cell sarcoma of sella turcica: successful treatment with adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Diagnosis, Differential; Humans; Male; | 2013 |
HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
Topics: 2-Methoxyestradiol; Adult; Animals; Antineoplastic Agents, Alkylating; Cell Survival; Dacarbazine; D | 2013 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cra | 2014 |
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.
Topics: Adenoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Blotting, Western; Dacarbazine; DNA Modific | 2014 |
Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
Topics: Adenocarcinoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Pitu | 2014 |
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Fem | 2015 |
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; | 2016 |
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Bi | 2015 |
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic | 2015 |
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow | 2016 |
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Topics: Adenoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Hypoxi | 2016 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbaz | 2016 |
Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Forecasting; Humans; Pituitary Neoplasms; | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; B | 2016 |
Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow-Up Studies; Humans; Image Pr | 2017 |
Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; Female; Humans; Pituitary Neoplasms; Prognosi | 2016 |
Refractory pituitary adenoma: a novel classification for pituitary tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Di | 2016 |
An unusual pituitary stalk lesion: What is the place of surgery?
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes | 2016 |
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2017 |
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
Topics: Adult; Cohort Studies; Dacarbazine; Gene Expression; Humans; Male; Middle Aged; O(6)-Methylguanine-D | 2009 |
Pituitary carcinoma presenting with multiple metastases: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Humans; Magnetic Res | 2008 |
Use of temozolomide in aggressive pituitary tumors: case report.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Cushing Syndrome; Dacarbazine; Female; Humans; Ma | 2009 |
High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine | 2009 |
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Female; Hormones; Humans; | 2009 |
A novel use of temozolomide in a patient with malignant prolactinoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prol | 2009 |
MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Dacarbazine; DNA Methylation; | 2010 |
SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant | 2010 |
Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
Topics: Adenoma; Clinical Trials as Topic; Dacarbazine; Humans; Pituitary ACTH Hypersecretion; Pituitary Neo | 2010 |
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; | 2010 |
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.
Topics: Antineoplastic Agents; Dacarbazine; DNA Methylation; Humans; Immunohistochemistry; O(6)-Methylguanin | 2010 |
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle Age | 2010 |
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Topics: ACTH-Secreting Pituitary Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Midd | 2011 |
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylati | 2011 |
MGMT immunoexpression in adamantinomatous craniopharyngiomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor | 2011 |
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Transformation, Neoplastic; Dacarbazine; DNA Modi | 2011 |
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinosarcoma; Dacarbazine; Humans; | 2011 |
Temozolomide and pituitary adenoma.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Humans; | 2011 |
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Nucleus; Dacarbazine; DNA Modification | 2011 |
New targeted therapies in pituitary carcinoma resistant to temozolomide.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Pituitary Neoplasms; | 2012 |
Anti-VEGF therapy in pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, H | 2012 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |
MGMT expression and pituitary tumours: relationship to tumour biology.
Topics: Adult; Aged; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Mid | 2013 |
Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Data Collection; DNA Modificat | 2013 |
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation | 2013 |
Temozolomide: a novel treatment for pituitary carcinoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma; Combined Modality Therapy; Dacarbazine; Humans; | 2006 |
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Topics: Antineoplastic Agents; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Te | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain | 2008 |
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Microscopy, Electron; Middle Aged; Pit | 2007 |
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Topics: Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Pituitary Ne | 2007 |
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dru | 2008 |